Possible 自主回収 against 東和薬品株式会社
For developers: integration details
You do not need this for normal browsing. Use it when integrating this enforcement record into an internal tool or AI workflow.
/api/v1/enforcements?company=%E6%9D%B1%E5%92%8C%E8%96%AC%E5%93%81%E6%A0%AA%E5%BC%8F%E4%BC%9A%E7%A4%BE&limit=10Action summary
- Company
- 東和薬品株式会社Japanese originalOriginal: 東和薬品株式会社
- Entity match
- Possible entity match60/100Machine extractedCompany name extracted from the Japanese public disclosure
- Governing law
- Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices薬機法
- Action type
- 自主回収自主回収
- Action date
- 16 September 2020
- Issuing authority
- Ministry of Health, Labour and Welfare厚生労働省
Violation
Product name: Metformin Hydrochloride Tablets 500mg MT "Towa"
Show original Japanese text
販売名：メトホルミン塩酸塩錠500mgMT「トーワ」
Compliance context
Context neededThis is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.
Health product law covering pharmaceuticals, medical devices, cosmetics, quasi-drugs, labeling, and advertising.
Review the original Japanese source and determine relevance to your counterparty-risk workflow.
This context is an operational aid for review workflows, not a credit opinion or legal conclusion.
Evidence pack
- Extracted at
- 2026-04-25T00:19:38.42+00:00
- Evidence checked
- 2026-04-25T00:19:38.42+00:00
- Archive captured
- 2026-04-09T12:01:40.165+00:00
Show audit JSON
{
"record": {
"id": "030b1ae0-537e-4ae1-90de-f23c125b4a8c",
"url": "https://regbase.jp/en/enforcement/yakkiho-dong-he-yao-pin-20200916",
"company_name_original": "東和薬品株式会社",
"company_name_registry": "東和薬品株式会社",
"corporate_number": null,
"law": {
"ja": "薬機法",
"en": "Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices"
},
"action_type": {
"ja": "自主回収",
"en": "自主回収"
},
"authority": {
"ja": "厚生労働省",
"en": "Ministry of Health, Labour and Welfare"
}
},
"entity_match": {
"status": "possible",
"confidence": 60,
"method": "extracted_japanese_name",
"method_label": "Company name extracted from the Japanese public disclosure",
"notes": null
},
"review": {
"status": "unreviewed",
"label": "Machine extracted"
},
"compliance_context": {
"severity": "Context needed",
"actionMeaning": "This is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.",
"practicalNote": "Review the original Japanese source and determine relevance to your counterparty-risk workflow.",
"lawContext": "Health product law covering pharmaceuticals, medical devices, cosmetics, quasi-drugs, labeling, and advertising."
},
"evidence": {
"recordUrl": "https://regbase.jp/en/enforcement/yakkiho-dong-he-yao-pin-20200916",
"officialSourceUrl": "https://www.mhlw.go.jp/stf/newpage_13602.html",
"archiveUrl": "https://kiroku.today/view/bcd066fa8crffbw2",
"archiveCapturedAt": "2026-04-09T12:01:40.165+00:00",
"extractedAt": "2026-04-25T00:19:38.42+00:00",
"translatedAt": "2026-05-01T07:08:10.185+00:00",
"evidenceCheckedAt": "2026-04-25T00:19:38.42+00:00",
"generatedAt": "2026-06-19T09:13:34.949Z"
},
"limitations": [
"RegBase aggregates public Japanese government disclosures and does not provide a credit opinion.",
"English summaries are provided for reference. The original Japanese source is authoritative.",
"Possible or unresolved entity matches should be manually verified before use in a decision."
]
}The original Japanese disclosure is the authoritative record. Use possible or unresolved matches only as leads for manual review.
Language
日本語版を見る (Japanese)About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.